Avantax Advisory Services Inc. Raises Holdings in Boston Scientific Corporation $BSX

Avantax Advisory Services Inc. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 16.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,719 shares of the medical equipment provider’s stock after acquiring an additional 7,103 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Boston Scientific were worth $5,340,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in BSX. Sound Income Strategies LLC raised its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific in the first quarter worth $27,000. Princeton Global Asset Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Boston Scientific by 72.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 145 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on BSX. Morgan Stanley raised their price target on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Truist Financial upped their target price on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Trading Down 2.5%

NYSE BSX opened at $99.23 on Wednesday. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $147.10 billion, a PE ratio of 53.06, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a fifty day moving average of $99.41 and a 200 day moving average of $102.51.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.